Department of Medicinal Chemistry and Molecular Pharmacology, Purdue Institute for Drug Discovery, Purdue University Center for Cancer Research, Purdue University, West Lafayette, IN 47907, USA.
Department of Biochemistry and Molecular Biology, Center for Computational Biology and Bioinformatics, Indiana University School of Medicine, Indianapolis, IN 46202, USA.
Molecules. 2022 Feb 18;27(4):1381. doi: 10.3390/molecules27041381.
Protein N-terminal methyltransferase 1 (NTMT1) recognizes a unique N-terminal X-P-K/R motif (X represents any amino acid other than D/E) and transfers 1-3 methyl groups to the N-terminal region of its substrates. Guided by the co-crystal structures of NTMT1 in complex with the previously reported peptidomimetic inhibitor DC113, we designed and synthesized a series of new peptidomimetic inhibitors. Through a focused optimization of DC113, we discovered a new cell-potent peptidomimetic inhibitor GD562 (IC = 0.93 ± 0.04 µM). GD562 exhibited improved inhibition of the cellular N-terminal methylation levels of both the regulator of chromosome condensation 1 and the oncoprotein SET with an IC value of ~50 µM in human colorectal cancer HCT116 cells. Notably, the inhibitory activity of GD562 for the SET protein increased over 6-fold compared with the previously reported cell-potent inhibitor DC541. Furthermore, GD562 also exhibited over 100-fold selectivity for NTMT1 against several other methyltransferases. Thus, this study provides a valuable probe to investigate the biological functions of NTMT1.
蛋白 N-端甲基转移酶 1(NTMT1)识别独特的 N 端 X-P-K/R 基序(X 代表除 D/E 之外的任何氨基酸),并将 1-3 个甲基基团转移到其底物的 N 端区域。在 NTMT1 与先前报道的肽模拟抑制剂 DC113 的共晶结构的指导下,我们设计并合成了一系列新的肽模拟抑制剂。通过对 DC113 的重点优化,我们发现了一种新的细胞有效肽模拟抑制剂 GD562(IC = 0.93 ± 0.04 µM)。GD562 对调节染色体凝聚 1 和致癌蛋白 SET 的细胞 N 端甲基化水平的抑制作用得到了改善,在人结直肠癌细胞 HCT116 中的 IC 值约为 50 µM。值得注意的是,与先前报道的细胞有效抑制剂 DC541 相比,GD562 对 SET 蛋白的抑制活性增加了超过 6 倍。此外,GD562 对 NTMT1 对其他几种甲基转移酶的选择性也提高了 100 多倍。因此,这项研究为研究 NTMT1 的生物学功能提供了一个有价值的探针。